Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Successful treatment of three patients with human immunodeficiency virus and hepatitis C virus genotype 1b co-infection by daclatasvir plus asunaprevir.

Clinical journal of gastroenterology - 1 Feb 2017

Hirashima Noboru, Iwase Hiroaki, Shimada Masaaki, Ryuge Nobumitsu, Imamura Junji, Ikeda Hiroki, Tanaka Yasuhito, Matsumoto Nobuyuki, Okuse Chiaki, Itoh Fumio, Yokomaku Yoshiyuki, Watanabe Tsunamasa

Abstract excerpt

Co-infection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) often accelerates the course of HCV-associated liver disease. Daclatasvir (DCV) plus asunaprevir (ASV) have been shown to be highly effective for HCV-infected patients with genotype 1b. Three patients co-infected with HIV/HCV genotype 1b were enrolled in this study. Prior to initiation of HCV treatment, the variants associated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Coinfection

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Imidazoles

Share to Isoquinolines

Share to Pyrrolidines

Share to Sulfonamides

Share to Valine

Source

Identifiers

PMID: 27766544
DOI: 10.1007/s12328-016-0693-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Successful treatment of three patients with human immunodeficiency virus and hepatitis C virus genotype 1b co-infection by daclatasvir plus asunaprevir.PMID 27766544Read ↗

Use of Daclatasvir in HCV/HIV-Coinfected Patients in a Real-Life Setting.Semantic proximity Read ↗

Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection.Semantic proximity Read ↗

Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIV.Semantic proximity Read ↗

Optimal therapy of HIV/HCV co-infected patients with direct acting antivirals.Semantic proximity Read ↗

Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world.Semantic proximity Read ↗

HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?Semantic proximity Read ↗

Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis.Semantic proximity Read ↗

Direct-acting Antivirals for HIV/HCV Co-infected Individuals: As Good as it Gets?Semantic proximity Read ↗

Daclatasvir, asunaprevir and beclabuvir fixed-dose combination for patients with genotype 1 chronic hepatitis C.Semantic proximity Read ↗

Mixed HCV Infection of Genotype 1B and Other Genotypes Influences Non-response during Daclatasvir + Asunaprevir Combination Therapy.Semantic proximity Read ↗

Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1.Semantic proximity Read ↗

NS5A resistance leading to failure of 24-week therapy with sofosbuvir/ledipasvir and ribavirin for the treatment of hepatitis C genotype 1a infection in a HIV-1 co-infected patient.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.